Innovation strategies in medicines and vaccines within the scope of CEIS – models, mechanisms, and expectations

Estrategias de innovación en medicamentos y vacunas en el ámbito del CEIS

Abstract

The article aimed to present relevant and original information about the innovation strategies used by  Official Pharmaceutical Laboratories (LFO) to reduce  the vulnerabilities of the Brazilian Unified Health  System (SUS) and the productive and technological  capacity of the Health Economic-Industrial Complex.  The methods used included a literature review and  the analysis of primary data from interviews conducted in two of the largest LFOs in the country.  Their efforts and results in Research and Development (R&D) and incorporation of medicines and vaccine  technologies were identified and analyzed, with  emphasis on Productive Development Partnerships  (PDP). Although R&D activities still need to advance,  benefits were brought about by technology transfer  agreements, especially by PDPs. However, the  industrial and technological capacity of the Institutes  is still limited and lacks investments, which hinders  technological accumulation and diffusion. Thus,  improvements are necessary so that the innovation  strategies for the SUS present more effective results  and can be reversed to the welfare of society.